TheStreet reissued their buy rating on shares of Baxter International (NYSE: BAX) in a research report released on Tuesday morning.

“Baxter International (BAX) has been reiterated by TheStreet Ratings as a buy with a ratings score of A . The company’s strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.”

,” TheStreet’s analyst commented.

TheStreet has also updated their ratings on a number of other healthcare stocks in the last week. The firm upgraded shares of NuVasive from a sell rating to a hold rating. Also, TheStreet upgraded shares of Merit Medical Systems to a buy rating.

Baxter International (NYSE: BAX) traded up 0.09% on Tuesday, hitting $69.98. Baxter International has a 1-year low of $48.98 and a 1-year high of $70.53. The stock’s 50-day moving average is currently $68.6. The company has a market cap of $38.204 billion and a price-to-earnings ratio of 16.73.

The company also recently announced a quarterly dividend, which is scheduled for Monday, April 1st. Shareholders of record on Friday, March 8th will be paid a dividend of $0.45 per share. This represents a $1.80 annualized dividend and a dividend yield of 2.57%. The ex-dividend date is Wednesday, March 6th.

BAX has been the subject of a number of other recent research reports. Analysts at EVA Dimensions downgraded shares of Baxter International to an overweight rating in a research note to investors on Tuesday, March 5th. Separately, analysts at RBC Capital reiterated an outperform rating on shares of Baxter International in a research note to investors on Thursday, February 21st. They now have a $72.00 price target on the stock. Finally, analysts at Zacks reiterated a neutral rating on shares of Baxter International in a research note to investors on Monday, January 28th. They now have a $71.00 price target on the stock.

Seven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $69.07.

Baxter International Inc. (NYSE: BAX) is a global, diversified healthcare company. Baxter, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.

To view TheStreet’s full report, visit www.thestreetratings.com

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.